Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Lizhu Group: The company's V-01 and V-01D-351 provide a better option for sequential strengthening
Published Time：
2022-07-21
Recently, an investor asked Lizhu Group on the interactive platform of the Shanghai Securities News, "In addition to V-01, does the company have any research and development related to the recently widely prevalent Omicron variant? What is the progress? "
Lizhu Group stated that it has been closely monitoring the global COVID-19 pandemic trend and the prevalence of COVID-19 variants, and is actively conducting research and development of variant vaccines. Relying on Lizhu's mature recombinant protein vaccine development platform, the company has developed a variety of variant vaccines, including Beta, Delta, and Omicron, as well as related bivalent vaccines, and has conducted relevant research on booster/sequential immunization in animals and researchers' clinical trials.
Recently, research data on the sequential booster vaccination of Lizhu Group's V-01 and bivalent vaccine V-01D-351 were published in the Journal of Clinical Medicine. The results showed that: In terms of immunogenicity, the sequential vaccination of V-01 and the V-01D-351 bivalent vaccine induced a more potent humoral immune response compared to homologous boosting. In terms of safety, the V-01 and V-01D-351 bivalent vaccines showed good safety and tolerability as sequential booster shots, with no or only mild adverse reactions. The V-01 sequential booster regimen also showed good immunogenicity and safety in elderly subjects. The V-01D-351 sequential booster regimen maintained effective immunogenicity against the wild-type strain and produced strong cross-neutralizing ability against Delta and Omicron BA.1. In addition, the immunogenicity of the V-01D-351 bivalent vaccine booster shot was maintained for a considerable period, with neutralizing antibody responses remaining at high levels up to 90 days post-vaccination. The positive results of this study will further promote the R&D process of V-01 and V-01D-351. The two studies provide a reasonable basis for the design of sequential booster vaccination regimens.
Source: Xinhua Net
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.